Nevro Corp ( (NVRO) ) has released its Q4 earnings. Here is a breakdown of the information Nevro Corp presented to its investors.
Nevro Corp., based in Redwood City, California, is a global medical device company specializing in innovative solutions for chronic pain management, with a focus on spinal cord stimulation systems and minimally invasive treatments.
In its latest earnings report, Nevro Corp. announced a decrease in revenue for both the fourth quarter and full-year 2024 compared to the previous year. Despite the decline, the company highlighted a strong balance sheet and successful restructuring efforts. Additionally, Nevro is set to be acquired by Globus Medical in an all-cash transaction valued at approximately $250 million.
Key financial metrics revealed a 9.1% decrease in worldwide revenue for the fourth quarter of 2024 compared to the same period in 2023, with U.S. revenue dropping by 9.9%. The company also reported a net loss from operations of $51.4 million for the quarter, exacerbated by a goodwill impairment charge. For the full year, Nevro’s revenue fell by 3.9%, and the net loss from operations increased to $126.2 million. However, adjusted EBITDA showed improvement, reflecting the company’s focus on cost management.
Looking ahead, Nevro’s management remains optimistic about the future, particularly with the upcoming acquisition by Globus Medical, which is expected to enhance their capabilities and market reach in chronic pain treatment solutions.